Supplemental Material from Toward Personalized Lymphoma Immunotherapy: Identification of Common Driver Mutations Recognized by Patient CD8+ T Cells

Supplemental Methods. Table S1. Frequency of hematopoietic subsets in PBMC at all time points for patient samples used for in vitro immunogenicity experiments Table S2: Clinical characteristics of follicular lymphoma cohorts Table S3. Amino acid changes encoded by somatic mutations identified in candidate genes in follicular lymphoma cohort Table S4. Patient HLA class I alleles for in vitro immunogenicity cohort Figure S1. The number of mutant peptides predicted to bind patient-specific HLA class I molecules in the sequencing cohort. Figure S2. Clinical timeline for 13-patient cohort selected for in vitro immunogenicity studies. Figure S3. CD8 status of mutant peptide-reactive T cells.